These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 14571193)

  • 21. Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors.
    Patel M; Ko SS; McHugh RJ; Markwalder JA; Srivastava AS; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Seitz SP
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2805-10. PubMed ID: 10522695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.
    Taylor S; Reynolds H; Sabin CA; Drake SM; White DJ; Back DJ; Pillay D
    AIDS; 2001 Oct; 15(15):2051-3. PubMed ID: 11600838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Non-nucleoside inhibitors of reverse transcriptase in therapy of HIV-infection].
    Galegov GA
    Antibiot Khimioter; 2005; 50(4):23-6. PubMed ID: 16392336
    [No Abstract]   [Full Text] [Related]  

  • 24. Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
    Gawali R; Trivedi J; Bhansali S; Bhosale R; Sarkar D; Mitra D
    Eur J Med Chem; 2018 Sep; 157():310-319. PubMed ID: 30099253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.
    Albright AV; Erickson-Viitanen S; O'Connor M; Frank I; Rayner MM; González-Scarano F
    AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1527-37. PubMed ID: 11054266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
    Ochoa de Echagüen A; Arnedo M; Xercavins M; Martinez E; Rosón B; Ribera E; Domingo P; González A; Riera M; Llibre JM; Gatell JM; Dalmau D;
    AIDS; 2005 Sep; 19(13):1385-91. PubMed ID: 16103769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
    Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
    SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
    Romines KR; Freeman GA; Schaller LT; Cowan JR; Gonzales SS; Tidwell JH; Andrews CW; Stammers DK; Hazen RJ; Ferris RG; Short SA; Chan JH; Boone LR
    J Med Chem; 2006 Jan; 49(2):727-39. PubMed ID: 16420058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants.
    Cancio R; Mai A; Rotili D; Artico M; Sbardella G; Clotet-Codina I; Esté JA; Crespan E; Zanoli S; Hübscher U; Spadari S; Maga G
    ChemMedChem; 2007 Apr; 2(4):445-8. PubMed ID: 17323401
    [No Abstract]   [Full Text] [Related]  

  • 30. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation.
    Tachedjian G; Moore KL; Goff SP; Sluis-Cremer N
    FEBS Lett; 2005 Jan; 579(2):379-84. PubMed ID: 15642347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
    Cocuzza AJ; Chidester DR; Cordova BC; Klabe RM; Jeffrey S; Diamond S; Weigelt CA; Ko SS; Bacheler LT; Erickson-Viitanen SK; Rodgers JD
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1389-92. PubMed ID: 11378361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
    Bastos MM; Costa CCP; Bezerra TC; da Silva FC; Boechat N
    Eur J Med Chem; 2016 Jan; 108():455-465. PubMed ID: 26708112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
    Cao YL; Li SX; Chen H; Guo Y
    Yao Xue Xue Bao; 2009 Apr; 44(4):355-61. PubMed ID: 19545051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian network analyses of resistance pathways against efavirenz and nevirapine.
    Deforche K; Camacho RJ; Grossman Z; Soares MA; Van Laethem K; Katzenstein DA; Harrigan PR; Kantor R; Shafer R; Vandamme AM;
    AIDS; 2008 Oct; 22(16):2107-15. PubMed ID: 18832874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Efavirenz Derivatives and 1,2,3-Triazolyl-phosphonates as Inhibitors of Reverse Transcriptase of HIV-1.
    Costa CCP; Boechat N; Bastos MM; da Silva FC; Marttorelli A; Souza TML; Baptista MS; Hoelz LVB; Cafffarena ER
    Curr Top Med Chem; 2018; 18(17):1494-1505. PubMed ID: 30370848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New reverse transcriptase inhibitors.
    Crowe S
    Adv Exp Med Biol; 1999; 458():183-97. PubMed ID: 10549391
    [No Abstract]   [Full Text] [Related]  

  • 38. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.
    Haubrich RH; Kemper CA; Hellmann NS; Keiser PH; Witt MD; Forthal DN; Leedom J; Leibowitz M; Whitcomb JM; Richman D; McCutchan JA;
    AIDS; 2002 Oct; 16(15):F33-40. PubMed ID: 12370520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Duchowicz PR; Fernández M; Caballero J; Castro EA; Fernández FM
    Bioorg Med Chem; 2006 Sep; 14(17):5876-89. PubMed ID: 16766190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Etravirine: genetic barrier and resistance development].
    Llibre JM; Santos JR; Clotet B
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():32-9. PubMed ID: 20116626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.